Literature DB >> 29478747

Congenital generalized lipodystrophy in Taiwan.

Rai-Hseng Hsu1, Wei-De Lin2, Mei-Chyn Chao3, Hui-Pin Hsiao4, Siew-Lee Wong5, Pao-Chin Chiu6, Shao-Yin Chu7, Yu-Yuan Ke8, Beng-Huat Lau9, Yin-Hsiu Chien1, Wuh-Liang Hwu1, Fuu-Jen Tsai10, Chung-Hsing Wang11, Ni-Chung Lee12.   

Abstract

BACKGROUND: Congenital generalized lipodystrophy (CGL) is a rare disorder characterized by scarce adipose tissue. This disease is distributed worldwide, but little is known about these patients in the Chinese population. Here, we delineate the phenotype and prognosis of CGL in our cohort.
METHODS: Patients diagnosed with CGL from 8 medical centers were reviewed. The initial presentation, laboratory findings, and molecular testing were retrospectively analyzed.
RESULTS: A total of 16 patients were analyzed, and the current median age was 3.5 years (range, 9 months-17.5 years). In all patients, molecular results confirmed BSCL2 mutation. c.782dupG (p.Ile262Hisfs*12) was the most common genotype identified. All patients had triangular faces and muscular hypertrophy. In addition, 75% presented with hepatomegaly, 19% had cardiomegaly, and 44% exhibited acanthosis nigricans. Developmental delay was noted in 5 out of 9 patients (56%) with a median developmental quotient (DQ)/intelligence quotient (IQ) of 61. Thirteen patients (81.3%) had high triglyceride levels. Eight patients received leptin analysis, and 7 of them (88%) had low leptin levels. One patient exclusively received a lipid-lowering drug, 4 patients were exclusively placed on a fat-restricted diet, 5 patients were administered combination therapy, and 5 patients received no treatment. Three patients (19%) who developed diabetes mellitus received both oral hypoglycemic agents and insulin. Three patients (19%) experienced loss of ambulation and died prematurely.
CONCLUSION: Our findings highlight the uniqueness of the genotype and phenotype in our cohort. Further long-term surveillance for comorbidities is necessary for early detection and management of these patients.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Congenital generalized lipodystrophy; Morbidity; Outcome

Mesh:

Substances:

Year:  2018        PMID: 29478747     DOI: 10.1016/j.jfma.2018.02.003

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  4 in total

Review 1.  Role of Seipin in Human Diseases and Experimental Animal Models.

Authors:  Yuying Li; Xinmin Yang; Linrui Peng; Qing Xia; Yuwei Zhang; Wei Huang; Tingting Liu; Da Jia
Journal:  Biomolecules       Date:  2022-06-17

2.  Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy.

Authors:  Josivan Gomes Lima; Lucia Helena C Nobrega; Natalia Nobrega Lima; Marcel Catão Ferreira Dos Santos; Pedro Henrique Dantas Silva; Maria de Fatima P Baracho; Debora Nobrega Lima; Julliane Tamara Araújo de Melo Campos; Leonardo Capistrano Ferreira; Francisco Paulo Freire Neto; Carolina de O Mendes-Aguiar; Selma Maria B Jeronimo
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

3.  RNA-seq of peripheral blood mononuclear cells of congenital generalized lipodystrophy type 2 patients.

Authors:  Yen-Hua Huang; Tzu-Chien Su; Chung-Hsing Wang; Siew-Lee Wong; Yin-Hsiu Chien; Yu-Tai Wang; Wuh-Liang Hwu; Ni-Chung Lee
Journal:  Sci Data       Date:  2021-10-13       Impact factor: 6.444

4.  Impaired functional exercise capacity and greater cardiovascular response to the 6-min walk test in congenital generalized lipodystrophy.

Authors:  Jorge Luiz Dantas de Medeiros; Bruno Carneiro Bezerra; Helen Rainara Araújo Cruz; Katarina Azevedo de Medeiros; Maria Eduarda Cardoso de Melo; Aquiles Sales Craveiro Sarmento; Marcela Abbott Galvão Ururahy; Lucymara Fassarella Agnez Lima; Alcebíades José Dos Santos Neto; Josivan Gomes Lima; Vanessa Resqueti; Lucien Peroni Gualdi; Guilherme Fregonezi; Julliane Tamara Araújo de Melo Campos
Journal:  BMC Cardiovasc Disord       Date:  2022-08-25       Impact factor: 2.174

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.